Ultragenyx Pharmaceutical (UP0) Stock Statistics & Valuation Metrics
Total Valuation
Ultragenyx Pharmaceutical has a market cap or net worth of EUR 1.42B. The enterprise value is EUR 4.31B.
- Market Cap
- EUR 1.42B
- Enterprise Value
- EUR 4.31B
Share Statistics
Ultragenyx Pharmaceutical has 98,588,875 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 98,588,875
- Owned by Insiders
- 3.94%
- Owned by Institutions
- 43.60%
Financial Efficiency
Ultragenyx Pharmaceutical’s return on equity (ROE) is 7.19 and return on invested capital (ROIC) is -43.53%.
- Return on Equity (ROE)
- 7.19
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -43.53%
- Return on Capital Employed (ROCE)
- -0.47
- Revenue Per Employee
- 490.88K
- Profits Per Employee
- -419.40K
- Employee Count
- 1,371
- Asset Turnover
- 0.44
- Inventory Turnover
- 2.10
Valuation Ratios
The current PE Ratio of Ultragenyx Pharmaceutical is -2.76. Ultragenyx Pharmaceutical’s PEG ratio is 0.44.
- PE Ratio
- -2.76
- PS Ratio
- 2.21
- PB Ratio
- -5.64
- Price to FCF
- -3.24
- Price to Operating Cash Flow
- -3.38
- PEG Ratio
- 0.44
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 673.00M and earned -575.00M in profits. Earnings per share was -5.83.
- Revenue
- 673.00M
- Gross Profit
- 564.00M
- Operating Income
- -535.00M
- Pretax Income
- -571.00M
- Net Income
- -575.00M
- EBITDA
- -474.00M
- Earnings Per Share (EPS)
- -5.83
Cash Flow
In the last 12 months, operating cash flow was -485.25M and capital expenditures -4.22M, giving a free cash flow of -489.47M billion.
- Operating Cash Flow
- -485.25M
- Free Cash Flow
- -489.47M
- Free Cash Flow per Share
- -4.80
Dividends & Yields
Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -30.84%
- Earnings Yield
- -35.74%
Stock Price Statistics
- Beta
- 0.89
- 52-Week Price Change
- -51.11%
- 50-Day Moving Average
- 14.64
- 200-Day Moving Average
- 19.64
- Relative Strength Index (RSI)
- 51.75
- Average Volume (3m)
- 289
Important Dates
Ultragenyx Pharmaceutical upcoming earnings date is Nov 03, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 03, 2026
- Ex-Dividend Date
- ―
Financial Position
Ultragenyx Pharmaceutical as a current ratio of 2.48, with Debt / Equity ratio of -1595.00%
- Current Ratio
- 2.48
- Quick Ratio
- 2.34
- Debt to Market Cap
- 0.55
- Net Debt to EBITDA
- -1.78
- Interest Coverage Ratio
- -8.63
Taxes
In the past 12 months, Ultragenyx Pharmaceutical has paid 4.00M in taxes.
- Income Tax
- 4.00M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Ultragenyx Pharmaceutical EV to EBITDA ratio is -5.63, with an EV/FCF ratio of -5.44.
- EV to Sales
- 3.72
- EV to EBITDA
- -5.63
- EV to Free Cash Flow
- -5.44
- EV to Operating Cash Flow
- -5.49
Balance Sheet
Ultragenyx Pharmaceutical has EUR 292.00M in cash and marketable securities with EUR 1.20B in debt, giving a net cash position of -EUR 910.00M billion.
- Cash & Marketable Securities
- EUR 292.00M
- Total Debt
- EUR 1.20B
- Net Cash
- -EUR 910.00M
- Net Cash Per Share
- -EUR 9.23
- Tangible Book Value Per Share
- -EUR 4.91
Margins
Gross margin is 83.12%, with operating margin of -73.77%, and net profit margin of -81.79%.
- Gross Margin
- 83.12%
- Operating Margin
- -73.77%
- Pretax Margin
- -81.25%
- Net Profit Margin
- -81.79%
- EBITDA Margin
- -65.98%
- EBIT Margin
- -70.63%
Analyst Forecast
The average price target for Ultragenyx Pharmaceutical is EUR 23.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 23.54
- Price Target Upside
- 62.68% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 21
- Revenue Growth Forecast
- 9.67%
- EPS Growth Forecast
- 1.87%
Scores
- Smart Score
- 6
- AI Score
- ―
